{
    "root": "2f76cd3b-fbfb-a193-e063-6294a90a1b32",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ATORVASTATIN CALCIUM",
    "value": "20250303",
    "ingredients": [
        {
            "name": "CALCIUM CARBONATE",
            "code": "H0G9379FGK"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (110000 WAMW)",
            "code": "5Y0974F5PW"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 101",
            "code": "7T9FYH5QMK"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 102",
            "code": "PNR0YF693Y"
        },
        {
            "name": "ATORVASTATIN CALCIUM TRIHYDRATE",
            "code": "48A5M73Z4Q"
        }
    ],
    "indications": "atorvastatin calcium tablets indicated : \u2022 reduce risk : myocardial infarction ( myocardial infarction ) , stroke , revascularization procedures , angina adults multiple risk factors coronary heart disease ( chd ) without clinically evident chd myocardial infarction stroke adults type 2 diabetes mellitus multiple risk factors chd without clinically evident chd non-fatal myocardial infarction , fatal non-fatal stroke , revascularization procedures , hospitalization congestive heart failure , angina adults clinically evident chd \u2022 adjunct diet reduce low-density lipoprotein cholesterol ( ldl-c ) : adults primary hyperlipidemia . adults pediatric patients aged 10 years older heterozygous familial hypercholesterolemia ( hefh ) . \u2022 adjunct ldl-c-lowering therapies , alone treatments unavailable , reduce ldl-c adults pediatric patients aged 10 years older homozygous familial hypercholesterolemia ( hofh ) . \u2022 adjunct diet treatment adults : primary dysbetalipoproteinemia hypertriglyceridemia",
    "contraindications": "\u2022 take orally daily without food ( 2.1 ) . \u2022 assess ldl-c clinically appropriate , early 4 weeks initiating atorvastatin calcium tablets , adjust necessary ( 2.1 ) . \u2022 adults ( 2.2 ) : recommended starting 10 20 mg daily ; range 10 mg 80 mg daily . patients requiring ldl-c reduction > 45 % may start 40 mg daily . \u2022 pediatric patients aged 10 years age older hefh : recommended starting 10 mg daily ; range 10 20 mg daily ( 2.3 ) . \u2022 pediatric patients aged 10 years age older hofh : recommended starting 10 20 mg daily ; range 10 80 mg daily ( 2.4 ) . \u2022 full prescribing information atorvastatin calcium tablets modifications due ( 2.5 ) .",
    "warningsAndPrecautions": "atorvastatin calcium tablets , usp supplied follows : 20 mg atorvastatin white off-white , oval , biconvex film coated tablets debossed '20 ' one side ' 54 ' side ndc 60760-883-90 bottles 90 storage store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "\u2022 acute liver failure decompensated cirrhosis [ ( 5.3 ) ] \u2022 hypersensitivity atorvastatin excipients atorvastatin calcium . hypersensitivity , including anaphylaxis , angioneurotic edema , erythema multiforme , stevens-johnson syndrome , toxic epidermal necrolysis , reported [ ( 6.2 ) ] .",
    "indications_original": "Atorvastatin calcium tablets\u00a0 are indicated:\u00a0 \n    \u2022 To reduce the risk of:\u00a0 \n    o Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with \n    \u00a0 \u00a0 \u00a0multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD\u00a0 \n    o MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD\u00a0 but without clinically evident CHD\u00a0 \n    o Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for\u00a0 \n    \u00a0 \u00a0 \u00a0congestive heart failure, and angina in adults with clinically evident CHD\u00a0 \n    \u2022 As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:\u00a0 \n    o Adults with primary hyperlipidemia.\u00a0 \n    o Adults and pediatric patients aged 10 years and older with heterozygous familial\u00a0 \u00a0 \u00a0 hypercholesterolemia (HeFH).\u00a0 \n    \u2022 As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).\u00a0 \n    \u2022 As an adjunct to diet for the treatment of adults with:\u00a0 \n    o Primary dysbetalipoproteinemia\u00a0 \n    o Hypertriglyceridemia",
    "contraindications_original": "\u2022 Take orally once daily with or without food ( 2.1 ). \u2022 Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating atorvastatin calcium tablets, and adjust dosage if necessary ( 2.1 ). \u2022 Adults ( 2.2 ): o Recommended starting dosage is 10 or 20 mg once daily; dosage range is 10 mg to 80 mg once daily. o Patients requiring LDL-C reduction >45% may start at 40 mg once daily. \u2022 Pediatric Patients Aged 10 Years of Age and Older with HeFH: Recommended starting dosage is 10 mg once daily; dosage range is 10 to 20 mg once daily ( 2.3 ). \u2022 Pediatric Patients Aged 10 Years of Age and Older with HoFH: Recommended starting dosage is 10 to 20 mg once daily; dosage range is 10 to 80 mg once daily ( 2.4 ). \u2022 See full prescribing information for atorvastatin calcium tablets dosage modifications due to drug interactions ( 2.5 ).",
    "warningsAndPrecautions_original": "Atorvastatin Calcium Tablets, USP are supplied as follows:\n                  \n                  20 mg of atorvastatin white to off-white, oval, biconvex film coated tablets debossed with '20' on one side and 'A 54' on other side\n                  \n                  NDC 60760-883-90 BOTTLES OF 90\n                  \n                  \n                  \n                  \n                     Storage\n                     \n                     \nStore at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "\u2022 Acute liver failure or decompensated cirrhosis\n \n  [see\n  \n   Warnings and Precautions (5.3)]\u00a0\n \n  \n                       \u2022 Hypersensitivity to atorvastatin or any excipients in atorvastatin calcium. Hypersensitivity reactions, including anaphylaxis, angioneurotic edema, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported\n \n  [see\n  \n   Adverse Reactions (6.2)]\n \n  ."
}